info:eu-repo/semantics/article
Association between Ancestry-Specific 6q25 Variants and Breast Cancer Subtypes in Peruvian Women
Fecha
2022-08-01Registro en:
10559965
10.1158/1055-9965.EPI-22-0069
15387755
Cancer Epidemiology Biomarkers and Prevention
2-s2.0-85135596165
SCOPUS_ID:85135596165
0000 0001 2196 144X
Autor
Zavala, Valentina A.
Casavilca-Zambrano, Sandro
Navarro-Vásquez, Jeannie
Castañeda, Carlos A.
Valencia, Guillermo
Morante, Zaida
Calderón, Monica
Abugattas, Julio E.
Gómez, Henry
Fuentes, Hugo A.
Liendo-Picoaga, Ruddy
Cotrina, Jose M.
Monge, Claudia
Neciosup, Silvia P.
Huntsman, Scott
Hu, Donglei
Sánchez, Sixto E.
Williams, Michelle A.
Núñez-Marrero, Angel
Godoy, Lenin
Hechmer, Aaron
Olshen, Adam B.
Dutil, Julie
Ziv, Elad
Zabaleta, Jovanny
Gelaye, Bizu
Vásquez, Jule
Gálvez-Nino, Marco
Enriquez-Vera, Daniel
Vidaurre, Tatiana
Fejerman, Laura
Institución
Resumen
Background: Breast cancer incidence in the United States is lower in Hispanic/Latina (H/L) compared with African American/ Black or Non-Hispanic White women. An Indigenous American breast cancer-protective germline variant (rs140068132) has been reported near the estrogen receptor 1 gene. This study tests the association of rs140068132 and other polymorphisms in the 6q25 region with subtype-specific breast cancer risk in H/Ls of high Indigenous American ancestry. Methods: Genotypes were obtained for 5,094 Peruvian women with (1,755) and without (3,337) breast cancer. Associations between genotype and overall and subtype-specific risk for the protective variant were tested using logistic regression models and conditional analyses, including other risk-associated polymorphisms in the region. Results: We replicated the reported association between rs140068132 and breast cancer risk overall [odds ratio (OR), 0.53; 95% confidence interval (CI), 0.47-0.59], as well as the lower odds of developing hormone receptor negative (HR-) versus HR+ disease (OR, 0.77; 95% CI, 0.61-0.97). Models, including HER2, showed further heterogeneity with reduced odds for HR+HER2+ (OR, 0.68; 95% CI, 0.51-0.92), HR-HER2+ (OR, 0.63; 95% CI, 0.44-0.90) and HR-HER2- (OR, 0.77; 95% CI, 0.56-1.05) compared with HR+HER2-. Inclusion of other risk-associated variants did not change these observations. Conclusions: The rs140068132 polymorphism is associated with decreased risk of breast cancer in Peruvians and is more protective against HR- and HER2+ diseases independently of other breast cancer-associated variants in the 6q25 region. Impact: These results could inform functional analyses to understand the mechanism by which rs140068132-G reduces risk of breast cancer development in a subtype-specific manner. They also illustrate the importance of including diverse individuals in genetic studies.